Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Angela Waszak"'
Autor:
Antoni Ribas, Mohammed Milhem, Diwakar Davar, Patricia LoRusso, Zeynep Eroglu, Martin Gutierrez, Arindam Dhar, Carlos Becerra, Brian Di Pace, Tianli Wang, Hailei Zhang, Srimoyee Ghosh, Shyam Srivats, Theo Borgovan, Angela Waszak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/124fe11cbcbd49b981727309c6d8f1f9
Autor:
Antoni Ribas, Zeynep Eroglu, Jose Manuel Manuel Trigo Perez, Brian Di Pace, Tianli Wang, Srimoyee Ghosh, Arindam Dhar, Theo Borgovan, Angela Waszak, Diwakar Davar
Publikováno v:
Journal of Clinical Oncology. 40:9513-9513
9513 Background: TIM-3 and PD-1 are markers of T-cell suppression that are upregulated in melanoma. AMBER (NCT02817633) is evaluating cobolimab (TSR-022/GSK4069889), an anti-TIM-3 therapy, monotherapy or with PD-1 inhibitors, including dostarlimab, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c66d9012e70ee5f77d1ca129288b4381
https://doi.org/10.1200/jco.2022.40.16_suppl.9513
https://doi.org/10.1200/jco.2022.40.16_suppl.9513
Autor:
Gerald Steven Falchook, Antoni Ribas, Diwakar Davar, Zeynep Eroglu, Judy S. Wang, Jason J. Luke, Erika P. Hamilton, Brian Di Pace, Tianli Wang, Srimoyee Ghosh, Arindam Dhar, Theo Borgovan, Angela Waszak, Patricia LoRusso
Publikováno v:
Journal of Clinical Oncology. 40:2504-2504
2504 Background: TIM-3 expressed on tumor-infiltrating T cells is associated with T-cell suppression. AMBER (NCT02817633) is evaluating cobolimab (TSR-022/GSK4069889) monotherapy and with PD-1 inhibitors in advanced solid tumors. Methods: Multi-cente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2ad4db78f97c3caf7bd76440bd59717
https://doi.org/10.1200/jco.2022.40.16_suppl.2504
https://doi.org/10.1200/jco.2022.40.16_suppl.2504